Investor Presentation Developing therapeutics for unmet medical needs in blockbuster markets, including a safe, non-addictive alternative to opioids
Disclaimer Certain statements contained in this presentation constitute forward-looking statements. The words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions typically are used to identify forward-looking statements. The use of forward-looking statements reflects our current views, expectations, estimates and/or projections with respect to our performance, business and future events, and in this presentation includes statements relating to, among others: expectations regarding our business; expectations relating to our business goals, objectives and schedules; expectations regarding interactions with regulatory authorities; expectations regarding our pre-clinical programs and clinical development plans; and expectations regarding development of new intellectual property. Forward-looking statements are based on the then-current expectations, forecasts and assumptions about the business and the industry and markets in which we operate, including, among others: that there will be no unforeseen delays, disruptions, market forces, regulations or laws that will prevent us from operating our business; and that we will be able to obtain the capital we require. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict, including, without limitation: that we may experience unforeseen delays, financing difficulties or costs that will impact our projects, operations, financial performance or liquidity; that we will not be able to advance our business plan or continue operations; that we will not be able to protect our intellectual property; that we will not be able to recruit and enroll patients for clinical trials; that we will not be able to successfully complete our clinical studies; that during clinical trials for products developed under our intellectual property may cause undesirable and potentially serious side effects which may delay or prevent regulatory approval, commercialization and market acceptance; that regulatory approvals of products developed from our intellectual property may result in significant delays; and those risks relating to the occurrence of national disasters, hostilities, acts of war or terrorism, our reputation, our key personnel, competition, employee relations, potential downturns in economic conditions, foreign exchange fluctuations, fluctuations in the currency markets, inflationary pressures, or changes in interest rates. These risks, as well as others, could cause actual results and events to differ materially from those anticipated in such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. These statements speak only as of the date of this presentation and we do not undertake any obligations to update such forward-looking statements, except as required by applicable securities law. Market and industry data contained in this presentation is based upon information, surveys or studies conducted by independent third parties and independent industry or general publications and our knowledge of, and experience in, the markets in which we operate or intend to operate. We have no reason to believe that such information is false or misleading in any material respect, however market and industry data is subject to variation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. This information has not been independently verified by us or any of our respective directors, officers or representatives and no representation is given as to the accuracy of any of the data from third party sources referred to in this presentation. 2
Overview Development stage pharmaceutical company targeting an out licensing or exit opportunity • Commercializing novel, patented, non-addictive endocannabinoid-boosting therapeutics. • The therapeutics were developed at the University of California, Irvine and result from over US$10M in past R&D spending. • Targeting significant unmet medical needs in multi-billion dollar markets. • Supported by non-dilutive grant funding. • Expects to be in clinical testing within 12 months. • Managed by a team of experienced biotech executives and entrepreneurs. Exxel Pharma is currently raising capital to run phase I clinical trials, list on the TSX Venture Exchange, and prepare for an exit or out licensing opportunity 3
Our Therapeutic Solution: The Endocannabinoid System The human endocannabinoid system (ECS) is biological system necessary for maintaining overall health and homeostasis. The Endocannabinoid System functions throughout the body The ECS impacts: • Pain • Mood • Anxiety • Appetite • Inflammation • Insomnia • Substance addiction 4
Endocannabinoid System: A Natural Opportunity The Endocannabinoid System The body’s own cannabinoid • The Endocannabinoid System (ECS) consists of Anandamide I. Endocannabinoids The name is taken from the II. Cannabinoid receptors Sanskrit word ananda which III. FAAH means "joy, bliss, delight", and amide, which refers to a class • Endocannabinoids are natural signaling molecules that activate of chemical compounds. the cannabinoid receptors; where and when needed • Cannabinoid receptors are found throughout the body (CB1 & CB2) Anandamide promotes health through • FAAH is an enzyme that disposes of endocannabinoids after they have served their function the cannabinoid receptors similar to CBD and THC from cannabis • The body’s natural endocannabinoid is called Anandamide 5
Making the Endocannabinoid System Work for Everyone Anandamide, THC and CBD promote therapeutic effects via the CB1 and CB2 receptors ü Therapeutic effects Anandamide ü The body’s natural molecule has few side-effects CB1/CB2 receptor ü Therapeutic effects THC ÷ Functional impairment (high), safety issues CB1/CB2 receptor ü Therapeutic effects CBD ÷ Drowsiness, unknown drug-drug interactions CB1/CB2 receptor Unfortunately, the behavioral and psychoactive effects of THC and CBD cannot be separated from their therapeutic effects, which limits their therapeutic value. 6
Boosting Anandamide to Deliver Novel Therapeutics Anandamide is disposed of by an enzyme named “FAAH” • FAAH (Fatty Acid Amide Hydrolase) breaks down anandamide • Preventing FAAH from destroying anandamide boosts anandamide’s therapeutic effects Anandamide FAAH enzyme FAAH inhibition is the mechanism behind Exxel’s therapeutics The therapeutic potential of blocking FAAH to boost Anandamide’s therapeutic effects is backed by comprehensive animal studies 7
Exxel Therapeutics: URB597 & URB937 Developed at University of California, Irvine Protected by issued patents Backed by world-class science Novel FAAH inhibitors: URB597 & URB937 URB597: • This therapeutic enters the Central Nervous System (CNS), enabling treatment of neurological disorders such as PTSD, substance addiction, MS, anxiety and insomnia. URB937: • In contrast to all other FAAH inhibitors, this therapeutic is excluded from the CNS and brain which provides a unique mechanism of action and superior pain management. Therapeutic & Commercial potential backed by comprehensive animal studies, peer-reviewed publications, and awards of NIH and DOD funding. 8
Advantages of URB597 and URB937 over Cannabis Small molecule therapeutics have multiple advantages over plant-derived cannabinoids. SMALL MOLECULES CANNABIS Synthetic Natural Issued patents Not patentable Safe/No side effects Causes functional impairment FDA approval (Legal) Controlled substance Easy dosage Inconsistent strength/effect Known drug-drug interactions Potentially fatal/unknown Doctor prescribed Self medication The behavioral and psychoactive effects of cannabis products cannot be separated from their therapeutic effects. 9
URB937: An Endocannabinoid-Targeting Therapeutic to Replace Prescription Opioid Analgesics Protected by issued and pending patents. Therapeutic and commercial potential: • Acute and chronic pain, migraine headache, hyperactive bladder, wound healing. • The drug is positioned as a safe, non-addictive alternative to opioids. An NIH STTR grant was awarded to prepare the drug for a phase I trial. An NIH grant was recently awarded to test URB937 as an opioid sparing therapy. The combination of animal data, patent protection and non-dilutive grant funding makes URB937 a significantly derisked asset with high commercial potential. 10
URB597: A Potential Therapeutic for PTSD and Substance Use Disorders The drug has broad therapeutic potential • PTSD, anxiety, depression, and opioid and other use disorders. PTSD-focused R&D is sponsored by the US Department of Defence. URB597 was previously approved for a phase I clinical trial by Health Canada. Exxel Pharma aims to start a first in man, phase I trial within 12 months. The combination of research data, prior regulatory approval, patent protection and non-dilutive grant funding supports the commercial potential of URB597. 11
Recommend
More recommend
